Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

被引：0
|
作者：
Shijie Lu
Yake Lou
Yi Rong
Zirui Huang
Xiaodan Lin
Junying Chen
Kongjia Luo
机构：
[1] Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[2] The Second Affiliated Hospital of Chongqing Medical University,Department of Cardiology
来源：
Clinical Drug Investigation | 2023年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：643 / 652
页数：9
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Rui Fang
    Suiqiong Wang
    Yongqian Liu
    Jun Xu
    Advances in Therapy, 2023, 40 : 1019 - 1030
  • [32] Cost-effectiveness analysis of sintilimab plus chemotherapy versus camrelizumab plus chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
    Rui, Mingjun
    Fei, Zhengyang
    Wang, Yingcheng
    Zhang, Xueke
    Ma, Aixia
    Sun, Haikui
    Li, Hongchao
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 618 - 629
  • [33] Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patients
    Wang, Z.
    Zhao, J.
    Ma, Z.
    Cui, J.
    Shu, Y.
    Liu, Z.
    Cheng, Y.
    Leaw, S.
    Wu, Y.
    Ma, Y.
    Tan, W.
    Wang, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1444
  • [34] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
    Xu, Jianming
    Kato, Ken
    Raymond, Eric
    Hubner, Richard A.
    Shu, Yongqian
    Pan, Yueyin
    Park, Sook Ryun
    Ping, Lu
    Jiang, Yi
    Zhang, Jingdong
    Wu, Xiaohong
    Yao, Yuanhu
    Shen, Lin
    Kojima, Takashi
    Gotovkin, Evgeny
    Ishihara, Ryu
    Wyrwicz, Lucjan
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Lin, Chen -Yuan
    Wang, Lei
    Shi, Jingwen
    Li, Liyun
    Yoon, Harry H.
    LANCET ONCOLOGY, 2023, 24 (05): : 483 - 495
  • [35] Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China
    Liu, Shixian
    Jiang, Nana
    Dou, Lei
    Li, Shunping
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [36] Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    Zhu, Huide
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 683 - 690
  • [37] Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Du, X.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S317 - S318
  • [38] Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    Zhu, Huide
    IMMUNOTHERAPY, 2023, 15 (13) : 1045 - 1055
  • [39] Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Zeng, Fan-Yuan
    Tang, Zi-Qing
    Zhou, Qin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Lin, Ying-Tao
    Zhou, Chong-Chong
    Xu, Kai
    Zhang, Meng-Die
    Li, Xin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
12345